MX2018003028A - Reduccion de los niveles o de la actividad de los linfocitos t reguladores sistemicos para el tratamiento de enfermedades y lesiones del sistema nervioso central (snc). - Google Patents

Reduccion de los niveles o de la actividad de los linfocitos t reguladores sistemicos para el tratamiento de enfermedades y lesiones del sistema nervioso central (snc).

Info

Publication number
MX2018003028A
MX2018003028A MX2018003028A MX2018003028A MX2018003028A MX 2018003028 A MX2018003028 A MX 2018003028A MX 2018003028 A MX2018003028 A MX 2018003028A MX 2018003028 A MX2018003028 A MX 2018003028A MX 2018003028 A MX2018003028 A MX 2018003028A
Authority
MX
Mexico
Prior art keywords
treatment
cns
injury
disease
activity
Prior art date
Application number
MX2018003028A
Other languages
English (en)
Inventor
Michal Eisenbach-Schwartz
BARUCH Kuti
ROSENZWEIG Neta
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/261,945 external-priority patent/US10519237B2/en
Priority claimed from PCT/IB2016/001433 external-priority patent/WO2017042633A2/en
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of MX2018003028A publication Critical patent/MX2018003028A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Manipulator (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente especificación revela una composición farmacéutica que comprende un agente activo que provoca la reducción del nivel de inmunosupresión sistémica en un individuo para uso en el tratamiento de una enfermedad, trastorno, condición o lesión del SNC; la composición farmacéutica se administra mediante un régimen de dosificación que comprende al menos una etapa de terapia, cada etapa de terapia comprende en secuencia una sesión de tratamiento seguida por una sesión de intervalo sin tratamiento.
MX2018003028A 2016-09-10 2017-09-08 Reduccion de los niveles o de la actividad de los linfocitos t reguladores sistemicos para el tratamiento de enfermedades y lesiones del sistema nervioso central (snc). MX2018003028A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15/261,945 US10519237B2 (en) 2014-03-12 2016-09-10 Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
PCT/IB2016/001433 WO2017042633A2 (en) 2015-09-10 2016-09-10 Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
PCT/IL2017/051011 WO2018047178A1 (en) 2016-09-10 2017-09-08 Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns

Publications (1)

Publication Number Publication Date
MX2018003028A true MX2018003028A (es) 2018-05-28

Family

ID=61561788

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018003028A MX2018003028A (es) 2016-09-10 2017-09-08 Reduccion de los niveles o de la actividad de los linfocitos t reguladores sistemicos para el tratamiento de enfermedades y lesiones del sistema nervioso central (snc).

Country Status (9)

Country Link
EP (2) EP4269439A3 (es)
JP (2) JP7074662B2 (es)
KR (2) KR20190050931A (es)
CN (2) CN108348607B (es)
AU (2) AU2017322656B2 (es)
CA (1) CA2997578A1 (es)
IL (4) IL300982B2 (es)
MX (1) MX2018003028A (es)
WO (1) WO2018047178A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
CN116640214A (zh) 2016-08-09 2023-08-25 科马布有限公司 分离抗体及其应用
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
EP3728314A1 (en) 2017-12-19 2020-10-28 Kymab Limited Bispecific antibody for icos and pd-l1
EP3801571A4 (en) * 2018-05-25 2022-08-10 Memorial Sloan Kettering Cancer Center DIAGNOSIS AND TREATMENT OF IMMUNOTHERAPY-INDUCED NEUROTOXICITY
CN112638944A (zh) 2018-08-23 2021-04-09 西进公司 抗tigit抗体
CN111956799A (zh) * 2020-09-18 2020-11-20 生物抗素公司 抗pd-1抗体和/或pd-l1抗体在制备治疗帕金森病药物中的应用
CN112569351B (zh) * 2020-12-16 2021-10-15 南通大学 Cd44抗体在制备治疗帕金森疾病的药物中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2468651A1 (en) * 2003-06-13 2004-12-13 Eleftherios P. Diamandis Detection of neurodegenerative diseases
CN1838950A (zh) * 2003-06-23 2006-09-27 神经化学（国际）有限公司 治疗蛋白质聚集疾病的方法
EP1678194B1 (en) * 2003-10-10 2013-06-26 Alchemia Oncology Pty Limited The modulation of hyaluronan synthesis and degradation in the treatment of disease
EP2545078A1 (en) * 2010-03-11 2013-01-16 UCB Pharma, S.A. Pd-1 antibody
CN102492038B (zh) 2011-12-09 2014-05-28 中国人民解放军军事医学科学院基础医学研究所 抗人Tim-3的中和性单克隆抗体L3D及其用途
US10183061B2 (en) * 2013-06-25 2019-01-22 Icm (Institut Du Cerveau Et De La Moelle Epiniere) Boosting Treg cells for treating Alzheimer disease and related disorders
WO2017042633A2 (en) * 2015-09-10 2017-03-16 Yeda Research And Development Co. Ltd Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
CN114081946A (zh) * 2014-03-12 2022-02-25 耶达研究与开发有限公司 降低系统性调节性t细胞水平或活性来治疗cns疾病和损伤
US9394365B1 (en) * 2014-03-12 2016-07-19 Yeda Research And Development Co., Ltd Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
TWI734975B (zh) * 2014-06-27 2021-08-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
JP7525980B2 (ja) * 2015-08-28 2024-07-31 アレクトル エルエルシー 抗Ｓｉｇｌｅｃ－７抗体及びその使用方法

Also Published As

Publication number Publication date
IL300982A (en) 2023-04-01
EP4269439A2 (en) 2023-11-01
CN116492457A (zh) 2023-07-28
IL291784B2 (en) 2023-09-01
EP4269439A3 (en) 2024-01-17
IL300982B2 (en) 2024-08-01
JP2019530635A (ja) 2019-10-24
IL257885B (en) 2022-05-01
IL300982B1 (en) 2024-04-01
AU2024203073A1 (en) 2024-05-30
AU2017322656B2 (en) 2024-02-29
WO2018047178A1 (en) 2018-03-15
CN108348607A (zh) 2018-07-31
CA2997578A1 (en) 2018-03-10
IL291784B1 (en) 2023-05-01
KR20190050931A (ko) 2019-05-14
JP2022106983A (ja) 2022-07-20
JP7074662B2 (ja) 2022-05-24
IL311841A (en) 2024-05-01
JP7451596B2 (ja) 2024-03-18
IL257885A (en) 2018-06-28
KR20240064742A (ko) 2024-05-13
EP3509636A1 (en) 2019-07-17
CN108348607B (zh) 2023-06-23
IL291784A (en) 2022-06-01
EP3509636A4 (en) 2020-12-16
AU2017322656A1 (en) 2018-04-19

Similar Documents

Publication Publication Date Title
MX2018003028A (es) Reduccion de los niveles o de la actividad de los linfocitos t reguladores sistemicos para el tratamiento de enfermedades y lesiones del sistema nervioso central (snc).
MX2021009611A (es) Reduccion de los niveles o la actividad de las celulas t reguladoras sistemicas para el tratamiento de enfermedad y lesion del sistema nervioso central (snc).
WO2017042633A3 (en) Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
MX2023012450A (es) Esketamina para el tratamiento de la depresion.
SG10201811185YA (en) Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii
MX2021013139A (es) Composicion farmaceutica para la prevencion y/o tratamiento de dermatitis atopica que comprende antagonista de interleucina 31 (il-31) como ingrediente activo.
EA201892657A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
MX2024010140A (es) Nuevos metodos.
MX2017017138A (es) Conjugados homogeneos especificos de sitio con inhibidores de ksp.
NZ792518A (en) Formulations for administration of eflornithine
MX2024002360A (es) Uso de estimuladores de la guanilato ciclasa soluble (sgc) para el tratamiento de trastornos mitocondriales.
WO2018102687A3 (en) Combination therapy for treating cancer
MX2023000187A (es) Dosificacion de vibegron para el tratamiento de vejiga sobreactiva.
PH12020551176A1 (en) Combination cancer therapy with pentaaza macrocyclic ring complex and platinum-based anticancer agent
MY186840A (en) Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy
MX2023007826A (es) Metodos que comprenden una dosificacion intermitente fija de cediranib.
MY180772A (en) Novel therapeutic mirtazapine combinations for use in pain disorders
MX2021011289A (es) Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas.
WO2016191458A3 (en) Pharmaceutical compositions affecting mitochondrial redox state and methods of treatment
MX2019013207A (es) Metodos y composiciones para tratar la endometriosis y sintomas asociados a la endometriosis.
AR116592A1 (es) Tratamiento de la colangitis biliar primaria y la colangitis esclerosante primaria con baricitinib
BR112019001808A2 (pt) composição farmacêutica anticâncer
WO2016154143A8 (en) Compositions and methods for treating copd and other inflammatory conditions
AR102494A1 (es) Métodos para tratar enfermedades oculares
ZA202102913B (en) Dosage regime